4-氟-2-羟基苯乙酮是一种低熔点固体,在较高环境温度下会呈现半固半液状态。它主要用作有机合成和医药化学中的中间体,广泛应用于激素及生物活性分子的合成过程中。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
4-氟苯乙酮 | 1-(4-Fluorophenyl)ethanone | 403-42-9 | C8H7FO | 138.141 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
4-氟-2-甲氧基苯乙酮 | 1-(4-fluoro-2-methoxy-phenyl)-ethanone | 51788-80-8 | C9H9FO2 | 168.168 |
—— | 2-ethyl-5-fluorophenol | 1147351-77-6 | C8H9FO | 140.157 |
—— | (E)-3-(dimethylamino)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one | 138469-95-1 | C11H12FNO2 | 209.22 |
—— | 1-(4-Fluor-2-hydroxyphenyl)-3-dimethylamino-2-propen-1-on | 138469-95-1 | C11H12FNO2 | 209.22 |
—— | 1-(2-ethoxy-4-fluorophenyl)ethanone | 51788-79-5 | C10H11FO2 | 182.195 |
2-溴-1-(4-氟-2-甲氧基苯基)乙酮 | 2-bromo-2'-methoxy-4'-fluoroacetophenone | 851634-64-5 | C9H8BrFO2 | 247.064 |
—— | (E)-1-(4-fluoro-2-hydroxyphenyl)-3-phenylprop-2-en-1-one | 1616578-12-1 | C15H11FO2 | 242.25 |
1-[4-氟-2-(甲氧基甲氧基)苯基]乙酮 | 1-[4-fluoro-2-(methoxymethoxy)phenyl]ethanone | 925922-96-9 | C10H11FO3 | 198.194 |
—— | 1-(2-(allyloxy)-4-fluorophenyl)ethanone | 956530-85-1 | C11H11FO2 | 194.206 |
—— | methyl 3-(4-fluoro-2-hydroxyphenyl)-3-oxopropanoate | 1204755-16-7 | C10H9FO4 | 212.177 |
1-[2-(2-氯乙氧基)-4-氟苯基]乙酮 | 1-[2-(2-chloroethoxy)-4-fluorophenyl]ethanone | 273722-55-7 | C10H10ClFO2 | 216.64 |
—— | 1-(4-fluoro-2-(prop-2-ynyloxy)phenyl)ethanone acid | 1160748-04-8 | C11H9FO2 | 192.19 |
—— | 1-[2-(ethoxymethoxy)-4-fluorophenyl]ethanone | 925922-53-8 | C11H13FO3 | 212.221 |
1-(3-氯-4-氟-2-羟基苯基)乙-1-酮 | 1-(3-chloro-4-fluoro-2-hydroxyphenyl)ethanone | 703-97-9 | C8H6ClFO2 | 188.586 |
—— | 1-(3-amino-4-fluoro-2-hydroxyphenyl)ethan-1-one | 1268629-02-2 | C8H8FNO2 | 169.155 |
—— | 1-(4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl)ethan-1-one | 220996-60-1 | C10H8F4O2 | 236.166 |
6-氟苯并呋喃-3(2H)-酮 | 6-fluoro-[2H]-benzofuran-3-one | 351528-80-8 | C8H5FO2 | 152.125 |
—— | (E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one | 1152162-38-3 | C15H10ClFO2 | 276.695 |
—— | 1-(4-fluoro-2-hydroxyphenyl)-3-(4-methoxylphenyl)prop-2-en-1-one | 392-08-5 | C16H13FO3 | 272.276 |
1-(2-(苄氧基)-4-氟苯基)乙酮 | 1-(2-(benzyloxy)-4-fluorophenyl)ethan-1-one | 106245-03-8 | C15H13FO2 | 244.265 |
—— | 4-fluoro-2-(oxiranylmethoxy)acetophenone | 107618-06-4 | C11H11FO3 | 210.205 |
4-氟-2-羟基苯乙酸 | 2-(4-fluoro-2-hydroxyphenyl)acetic acid | 31338-67-7 | C8H7FO3 | 170.14 |
—— | 1-[4-fluoro-2-(2-morpholin-4-ylethoxy)phenyl]ethanone | 1282851-09-5 | C14H18FNO3 | 267.3 |
—— | 4-fluoro-2-(4-pyridinylmethoxy)acetophenone | 153411-30-4 | C14H12FNO2 | 245.253 |
—— | Ethyl 2-(2-acetyl-5-fluorophenoxy)acetate | 926648-01-3 | C12H13FO4 | 240.231 |
—— | 1-(2-(benzyloxy)-4-fluorophenyl)-2-bromoethan-1-one | 719288-25-2 | C15H12BrFO2 | 323.161 |
—— | O-2-acetyl-5-fluorophenyl N,N-dimethylcarbamothioate | 1227191-46-9 | C11H12FNO2S | 241.286 |
—— | 2'-hydroxy-4'-methylthioacetophenone | 93175-16-7 | C9H10O2S | 182.243 |
—— | 6-fluoro-2-hydroxybenzofuran-3(2H)-one | 1613044-64-6 | C8H5FO3 | 168.124 |
Isoliquiritigenin (ISL), a natural product isolated from licorice root, exhibits anti-gastric cancer effects. However, applications of ISL are still limited in clinical practice due to its poor bioavailability. To discovery of more effective anti-gastric cancer agents based on ISL, aldol condensation reaction was applied to synthesize the ISL analogues. MTS assay was used to evaluate the inhibitory activities of ISL analogues against SGC-7901, BGC-823 and GES-1 cells in vitro. Cell cycle distribution, apoptosis and reactive oxygen species (ROS) generation were detected by flow cytometry. Western blot assay was used to analyze the expression levels of related proteins. The drug-likeness and pharmacokinetic properties were predicted with Osiris property explorer and PreADMET server. As a result, 18 new ISL analogues (ISL-1 to ISL-18) were synthesized. Among these analogues, ISL-17 showed the strongest inhibitory activities against SGC-7901 and BGC-823 cells, and could induce G2/M cell cycle arrest and apoptosis in these two cell lines. Treatment with ISL-17 resulted in increased ROS production and elevated autophagy levels in SGC-7901 cells. The PI3K/AKT/mTOR signaling pathway was down-regulated after treatment with ISL-17 in SGC-7901 cells. The results of drug-likeness and pharmacokinetic prediction indicated that all the ISL analogues complied with Lipinski's rule of five and Veber rule and had a favorable ADME character. Overall, our results attest that ISL-17 holds promise as a candidate agent against gastric cancer.